Scribe Therapeutics, Inc.
Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for cardiometabolic diseases.
424B4Sep 28Latest SEC filing
Sep 2Latest story
Sign inSign inScribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for cardiometabolic diseases.